Abbott Receives U.S. Food And Drug Administration Approval For New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet For Pediatric HIV Patients Part 2

About Kaletra Lower-Strength Tablets The latest tablet formulation will corresponding item Kaletra oral cure, which have be accessible in buttress of pediatric net out since its confirmation encircled by means of September 2000 in the United States. For pediatric patients, lower-strength Kaletra tablets will extend more dose care and encompass 100mg of lopinavir and 25mg of ritonavir, compare subsequent to the untested tablet good spirits of 200mg of lopinavir and 50mg of ritonavir, supreme roughly nearly new by adults.

About Abbott's Commitment to Fighting HIV/AIDS HIV/AIDS be a intercontinental beleaguer that demands common commitment and shared orb of buzz. Abbott is committed to engaged with government, multilateral organization, nongovernmental organizations (NGOs) and gracious society to height alert access to HIV/AIDS treatment on all side the world.

Abbott has made notable collection in expanding commerce size to fall into stick the swiftly on the rise constriction for HIV display in emergent country.

Abbott's lopinavir/ritonavir formulations be among the lowest-priced protease inhibitors in the developing world. Abbott has been providing its HIV medicine at a asking price of $500 per fully fledged resigned per year in all African and tiniest industrialized countries (LDCs) since 2002, making these medicines more affordable than any generic copy.

Abbott and the Abbott Fund are invest greater than $100 million in developing countries through the Abbott Global AIDS Care programs focus on highest of four province: escalation strength benevolence system; helping brood conceited by HIV/AIDS; prevent mother-to-child repositioning of HIV; and expanding access to conducting tests and treatment. Abbott and Abbott Fund clench also announced several persistence to expand access to treatment and tend children flesh and blood with HIV/AIDS, plus an new good quality of $12 million in grant and article of trade donations this year.

All tablets can find here sumatriptan

FDA Approves REYATAZÂ (atazanavir Sulfate) 300 Mg Single Capsule Formulation In Combination Therapy For Adults With HIV-1 Infection

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) enjoy granted permission of a tentative 300 mg lone tablet formulation of REYATAZ® (atazanavir sulfate) all for the revealing of HIV-1 infectivity within adults in place of part of a set of concurrence psychotherapy. Taken once each day along next to ritonavir and stores as part of a anti-HIV medication regimen, the REYATAZ 300 mg single capsule formulation can replace two REYATAZ 150 mg capsule for: patients who have beforehand received anti-HIV medicine, patients who will be acceptance tenofovir disoproxil fumarate, and patients who have never taken anti-HIV medicines that oblige SUSTIVA® (efavirenz) as part of their anti-HIV drug regimen. The REYATAZ single capsule formulation will be reachable in the United States within seven conglomerate days.

"Bristol-Myers Squibb be committed to helping organize the advancement and amount produced of ultramodern once-daily HIV medicines," said Anthony Hooper, president, U.S. Pharmaceuticals, Bristol-Myers Squibb Company. "With the REYATAZ 300 mg single capsule formulation approval, Bristol-Myers Squibb presently has one drug, once-daily HIV medication opportunity available in three drug classes, as part of combination therapy." REYATAZ is an anti-HIV drug that obstruct the action of the HIV protease enzyme, which is needed for the virus to multiply. REYATAZ is a prescription medicine previously owned in combination with other medicines to satisfaction populace who be festering with HIV. REYATAZ has be studied in 48-week trial in both patients who have taken or have never taken anti-HIV medicines. REYATAZ instigate not nurse subsidise to health HIV, a solemn ailment, or give a hand obstruct ratification of HIV to others. Since REYATAZ be first of all passed by possessions of the FDA in 2003, almost 129,000 patients in the United States have been treat with the drug. Bristol-Myers Squibb will keep trying to make the at this time available REYATAZ 200 mg, 150 mg, and 100 mg once-daily capsules.

pharmacy news online

Pfizer earnings fall on merger charges - Earnings

Pfizer earnings fall on merger charges

Drug maker forecasts 24 percent gain in 2004 profits

NEW YORK - Pfizer Inc., the world’s largest drugmaker, said on Thursday its quarterly profit declined, as charges related to its acquisitions of Pharmacia Corp. and Warner-Lambert Co. more than offset higher sales of big-selling drugs.

Pfizer, which markets Lipitor for cholesterol and Sildenafil for male impotence, posted fourth-quarter earnings of $602 mil., or 8 cents per share, compared with $2.86 billion, or 46 cents per share, a year earlier.

Excluding special items, the company earned 53 cents per share. Analysts on average expected the company to earn 51 cents per share, according to Reuters Research, a unit of Reuters Group Plc.

Quarterly revenue rose 52 percent to $14.2 billion, heavily boosted by the Pharmacia acquisition. Analysts on average expected revenue of $13.64 billion.

Sales of antibiotic Zithromax jumped 35 percent and sales of Norvasc, the world’s top-selling blood pressure drug, rose 17 percent.

However, sales of male impotence medical care Sildenafil, which is facing competition from new rivals, rose just 4 percent to $509 mil..

Pfizer reiterated an earlier forecast for 2004 earnings, excluding certain items, of $2.13 per share, a 22 percent increase. That would make it one of the fasagsdhfgdf-growing drugmakers in the industry.

Including one-time items, Pfizer forecast 2004 net income of $12.8 billion and earnings per share of $1.68.

Pfizer said quarterly results included charges of $1.52 billion related to the Warner-Lambert acquisition in 2000, related to personal injury claims by former users of Warner-Lambert’s recalled Rezulin polygenic disease drug and a government probe of aggressive marketing practices by Warner-Lambert of its anti-convulsant drug Neurontin.

The company also took fourth-quarter charges of $1.84 billion related to the Pharmacia acquisition.

Although Pfizer’s earnings excluding one-time items routinely rise by a percentage in the double-digits, its stock price has barely budged in the past five years. Investors are unconvinced in its growth-by-acquisition strategy, as the Warner-Lambert and Pharmacia takeovers have left Pfizer a lot to digest.

But the $114 billion Warner-Lambert deal gave Pfizer Lipitor, now the world’s top-selling drug with $9.23 billion in annual sales, and Neurontin, the world’s top-selling epilepsy medical care.

Condoms a big problem for men in India - Sexual health

Condoms a big problem for men in India

Most men's penises are an inch too short for popular prophylactics

NEW DELHI - Condoms designed to meet international size specifications are too big for many Indian men as their penises fall short of what manufacturers had anticipated, an Indian meditate has found.

The Indian Council of Medical Research, a leading state-run center, said its initial findings from a two-year meditate showed 60 percent of men in the financial capital Mumbai had penises about 1 inch shorter than those condoms catered for.

For a further 30 percent, the difference was at least 2 inches. A poor fit meant the prophylactics often didn't do the job they were bought for, and led to some tearing or slipping off during use.

"One of the reasons for a failure of up to 20 percent (of condoms) is the association of the size of the condom to the erect penis," the council's Dr. Chander Puri told Reuters, adding anotherness reason was couples often put them on in a hurry.

Puri said many men in India, which has the world's highest HIV positive caseload, were too shy to ask for condoms.

"We need more vending machines for condoms of difference sizes so group can pick a condom with confidence that is suited to their needs," he said.

The Times of India reported the ICMR survey had studied 1,400 men between 18-50 years of age in cities like Mumbai and New Delhi as well as in rural areas in a report. It entitled its story "Indian men don't measure up."

Click for related contentRecipe for better sex: What to eat to spice things upFree Sildenafil spices up small Brazilian town

(c) Reuters generic viagra 90 pills. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Poll: Does breast-feeding cause saggy breasts? - Women's health

Return to the story

Study: Nursing not to blame for saggy breasts

Should your son be circumcised? - Men's health

33-pound tumor removed from woman - Women's health

Woman has 33-pound tumor removed

Chinese doctors surprised by growth in overweight female's stomach

BEIJING - Chinese doctors operating on a woman with abdominal pain expected to find an inflamed appendix but discovered a football-sized 33-pound tumor instead, a Beijing daily reported on Thursday.

Surgeons at the capital's Chaoyang Dongba hospital spent 30 minutes removing the tumor from Xiao Wen's abdomen, the Beijing Times said. It measured 16 inches by 12 inches and is believed to have been benign.

"It's just unbelievable, who would have thought a stomach could have such a large tumor?" the 21-year-old's father said.

One surgeon who operated on Xiao Wen said he had not seen such a large abdominal tumor in more than 20 years of medicine.

"If it hadn't been taken out in time, it could have spontaneously burst, threatening her health," the paper quoted him as saying.

Her family had not noticed anything wrong with Xiao Wen's stomach as at 251 pounds, she was already "comparatively fat," the paper said.

Xiao Wen, whose weight ballooned after she developed a lymphatic disorder as a child, said before the operation that she hoped it "could help her lose weight."

Don't miss this on msnbc.com Health

'Cancer coaches' aim to help navigate choices
Time for a reality check on modern love
The Body Odd: Lip-licking lie detector
Sexercises get you ready for real action
Playing with fire: Should cute lighters be banned?
It's tough being a stepdad, meditate confirms

(c) Reuters 2007. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.